Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Ifenprodil for the Treatment of Flashbacks in Adolescent Female Posttraumatic Stress Disorder Patients with a History of Abuse

Psychother Psychosom (2013) 82 (5): 344–345.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double‐blind, placebo‐controlled trial
  • Hiroko Kotajima‐Murakami
  • Ayumi Takano
  • Shinya Hirakawa
  • Yasukazu Ogai
  • Daisuke Funada
  • Yuko Tanibuchi
  • Eriko Ban
  • Minako Kikuchi
  • Hisateru Tachimori
  • Kazushi Maruo
  • Takahiro Kawashima
  • Yui Tomo
  • Tsuyoshi Sasaki
  • Hideki Oi
  • Toshihiko Matsumoto
  • Kazutaka Ikeda
Neuropsychopharmacology Reports (2022) 42 (1): 92.
Ifenprodil tartrate treatment of adolescents with post-traumatic stress disorder: A double-blind, placebo-controlled trial
  • Tsuyoshi Sasaki
  • Kenji Hashimoto
  • Tomihisa Niitsu
  • Yutaka Hosoda
  • Yasunori Oda
  • Yuki Shiko
  • Yoshihito Ozawa
  • Yohei Kawasaki
  • Nobuhisa Kanahara
  • Akihiro Shiina
  • Tasuku Hashimoto
  • Takaaki Suzuki
  • Takeshi Sugawara
  • Hideki Hanaoka
  • Masaomi Iyo
Psychiatry Research (2022) 311: 114486.
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
  • Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2021) 271 (2): 249.
Centrally acting anticholinergic drug trihexyphenidyl is highly effective in reducing nightmares associated with post‐traumatic stress disorder
  • Katsumasa Sogo
  • Masanobu Sogo
  • Yoshie Okawa
Brain and Behavior (2021) 11 (6)
d-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders
  • Herman Wolosker
  • Darrick T. Balu
Translational Psychiatry (2020) 10 (1)
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
  • Hazem Ahmed
  • Ahmed Haider
  • Simon M. Ametamey
Expert Opinion on Therapeutic Patents (2020) 30 (10): 743.
Theranostic pharmacology in PTSD: Neurobiology and timing
  • Ralph J. Koek
  • Tinh N. Luong
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) 90: 245.
σ1 receptor ligands control a switch between passive and active threat responses
  • Andrew J Rennekamp
  • Xi-Ping Huang
  • You Wang
  • Samir Patel
  • Paul J Lorello
  • Lindsay Cade
  • Andrew P W Gonzales
  • Jing-Ruey Joanna Yeh
  • Barbara J Caldarone
  • Bryan L Roth
  • David Kokel
  • Randall T Peterson
Nature Chemical Biology (2016) 12 (7): 552.
Blocking GluN2B subunits reverses the enhanced seizure susceptibility after prolonged febrile seizures with a wide therapeutic time-window
  • Bin Chen
  • Bo Feng
  • Yangshun Tang
  • Yi You
  • Yi Wang
  • Weiwei Hou
  • Weiwei Hu
  • Zhong Chen
Experimental Neurology (2016) 283: 29.
Glutamatergic system abnormalities in posttraumatic stress disorder
  • Daisuke Nishi
  • Kenji Hashimoto
  • Hiroko Noguchi
  • Kei Hamazaki
  • Tomohito Hamazaki
  • Yutaka Matsuoka
Psychopharmacology (2015) 232 (23): 4261.
Presence of psychological distress symptoms associated with onset-related life events in patients with treatment-refractory depression
  • Atsushi Kimura
  • Tasuku Hashimoto
  • Tomihisa Niitsu
  • Masaomi Iyo
Journal of Affective Disorders (2015) 175: 303.
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication
  • Kenji Hashimoto
Journal of Pharmacological Sciences (2015) 127 (1): 6.
Ifenprodil
Reactions Weekly (2015) 1539 (1): 167.
Old drug ifenprodil, new hope for PTSD with a history of childhood abuse
  • Kenji Hashimoto
  • Tsuyoshi Sasaki
  • Akira Kishimoto
Psychopharmacology (2013) 227 (2): 375.
  • Online ISSN 1423-0348
  • Print ISSN 0033-3190
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal